Initial formation of IGROV1 ovarian cancer multicellular aggregates involves vitronectin.
Ovarian cancer progression is frequently associated with the development of malignant ascites. Multicellular aggregates of carcinoma cells (spheroids) found within ascites are thought to be able to promote peritoneal carcinomatosis. We have previously demonstrated the involvement of the vitronectin/alphav integrin adhesive system in the dissemination of ovarian cancer cells and continue to investigate the influence of these molecules by studying their role(s) in spheroid behavior. The aim of this study was to generate ovarian cancer multicellular aggregates and to focus on the role of vitronectin and alphav integrins in their initiation. IGROV1 cancer cells cultured in the absence of adhesive substratum formed multicellular aggregates comparable to spheroids. After 21 days, a fraction of the cells within clusters remained viable and proliferated recurrently. Within the multicellular aggregates, vitronectin and alphav integrins were co-localized at intercellular sites, suggesting their involvement in cell-cell interactions. Initial formation of IGROV1 aggregates was inhibited using anti-vitronectin and anti-alphav integrin blocking antibodies or the cyclic peptide cRGDfV. Vitronectin expression persisted during cluster disaggregation on fibronectin. These results demonstrate the ability of IGROV1 cells to generate multicellular aggregates and point to a contributory role for the vitronectin/alphav integrin system in the initial step of this process. These events could represent a prerequisite for further dissemination.
Kellouche
Sabrina
S
ERRMECe, EA 1391, Institut des materiaux, UFR Sciences et Techniques, Université de Cergy Pontoise, 2 rue Adolphe Chauvin, 95302, Cergy-Pontoise Cedex, France.
Fernandes
Julien
J
Leroy-Dudal
Johanne
J
Gallet
Olivier
O
Dutoit
Soizic
S
Poulain
Laurent
L
Carreiras
Franck
F
D000230:Adenocarcinoma / Q000473:pathology*; D002448:Cell Adhesion; D002449:Cell Aggregation; D045744:Cell Line, Tumor; D005260:Female; D006801:Humans; D039564:Integrin alphaV / Q000032:analysis / Q000502:physiology; D010051:Ovarian Neoplasms / Q000473:pathology*; D019096:Vitronectin / Q000032:analysis / Q000502:physiology*
D039564:Integrin alphaV; D019096:Vitronectin